Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

FLUODIAMON · Ultra-high resolution and ultra-sensitive fluorescence methods for objective sub-cellular diagnosis of early disease and disease progression in breast and prostate cancer

FP7Status: CLOSED1 June 200831 May 2012EU funding €4,197,774

The overall objective of this proposal is to develop and validate a quantitative, minimally invasive diagnostic tool for early and conclusive detection, diagnosis and monitoring of disease and disease progression of breast and prostate cancer. A methodology will be developed making use of a combination of the probably most exciting recent advances in the field of light microscopy, for fluorescence-based optical imaging of individual sample cells. It includes advances which will take the spatial resolution far beyond the fundamental limits of optical resolution, the sensitivity down to an ultimate single-molecule level, and multi-parameter detection schemes significantly increasing the fluorescence information by which these cellular images can be analysed. Apart from detecting and identifying tumour markers in the samples, tumour-specific spatio-temporal molecular distributions within the intact sample cells will be exploited. This is to date an almost unexploited dimension of diagnostic information. By combining and supporting these novel optical methods with state-of-the-art affinity molecule biotechnology, , tumor biomarkers, fluorophore chemistry, and bioinformatic validation tools, all possible means will be exploited to extract a maximum amount of information out of very small amounts of sample material. We thereby expect that an improved, early and reliable diagnosis of breast and prostate cancer will be possible, from amounts of sample material small enough that a minimally invasive procedure such as Fine-needle aspiration (FNA) can be used. In addition, by the minimally invasive FNA-based sampling, serious sampling-related side-effects, such as seeding and spread of cancer cells can be completely avoided. Given the high incidence of breast and prostate cancer, and the utmost importance of an early and conclusive diagnosis for the prognosis of these diseases, the relevance of this project can not be overestimated.

Consortium · 12 organisations

coordinator

KUNGLIGA TEKNISKA HOEGSKOLAN

SE · €1,101,193

participant

ACADEMISCH ZIEKENHUIS LEIDEN

NL · €261,009

participant

UNIVERSITAET SIEGEN

DE · €177,112

participant

HEINRICH-HEINE-UNIVERSITAET DUESSELDORF

DE · €451,958

participant

BECKER & HICKL GMBH

DE · €285,314

participant

HELSINGIN YLIOPISTO

FI · €128,604

participant

NEODYNAMICS AB

SE · €265,430

participant

KAROLINSKA INSTITUTET

SE · €333,963

participant

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

DE · €351,116

participant

SENSL TECHNOLOGIES LIMITED

IE · €361,557

participant

UNIVERSITAET zu LUEBECK

DE · €270,192

participant

TURUN YLIOPISTO

FI · €210,326

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.